AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion – United Cultures

Cultural Unity and Shared ValuesDevelopment CooperationGlobal AlliancesGlobal CitizenshipGlobal Economic Shifts

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

July 14, 2026

0

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment.

Evolve Internet Smart Technology